Els Beirnaert, PhD and CEO of Aelin Therapeutics, brings along 19 years of experience in drug development, venture and business development. Previously she was one of the start-up pioneers of Ablynx a company established in 2001 focused on biological therapeutics. She was leading multidisciplinary project teams and translating several drug development projects from discovery to clinical development (Phase 1 and 2). Since 2010, she was Head of New Ventures at VIB responsible for the establishment of multiple start-up companies in life sciences. She served in the board of directors of Confo Therapeutics, Q-Biologicals and Multiplicom. Dr. Beirnaert obtained a Master in Biotechnology at the University of Ghent and a PhD in Biochemistry at the Institute of Tropical medicine (University of Antwerp).